GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth. Credit: Jason Alden/Bloomberg Subscribe now Already have an account? Sign in.
